Product Description
Mechanisms of Action: LTB4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Pancreatic Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Protocol H6H-MC-JEAI | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2003-02-01 |
|
| H6H-MC-JEAM | P2 |
Completed |
Non-Small-Cell Lung Cancer |
None |
|
| H6H-MC-JEAL | P2 |
Completed |
Pancreatic Cancer |
None |